default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Celltrion marks robust Q3 sales

Lee Han-soo  Published 2019.11.07  14:03  Updated 2019.11.07 14:03

공유
default_news_ad2

Celltrion said that it has recorded sales of 289.1 billion won ($249 million) in the third quarter, up 25.1 percent from a year earlier. The company also registered 103.1 billion won in operating profit, a hefty increase of 40.1 percent.

Celltrion headquarters in Incheon.

“Our company has shown growth throughout its product portfolio, such as the EU launch of Remsima SC after receiving approval from the European Medicines Agency (EMA) and market expansion of Truxima, which the company is planning to launch in the U.S.," the company said. "Turnover also increased thanks to robust sales of chemical drugs from Celltrion Pharmaceutical and the Ajovy contract manufacturing organization (CMO) contract with Teva, a multinational pharmaceutical company."

The market shares of Celltrion’s primary products, such as Remsima, Truxima, and Herzuma, are stably expanding in Europe, the company said, adding that it plans to complete the approval process of more than one biosimilar product annually until 2030.

Aside from the commercially available Remsima, Truxima and Herzuma, the company is developing an Avastin biosimilar CT-P16 for colorectal cancer, Humira biosimilar CT-P17 for autoimmune diseases, Xolair biosimilar CT-P39 for allergic asthma and chronic urticarial, Celltrion said in a press release.

The company also noted that it is developing cell lines and started processes for more than 15 subsequent biosimilar candidates.

"In the third quarter, both sales and operating profit increased, aided by the early launch of Remsima SC following the EMA approval and supply growth accompanying our plan to launch Truxima in the U.S.," a company official said.

The global market share of Celltrion products continues to rise, and the company will be able to secure a top-tier portfolio as it plans to receive approval for one or more biosimilars annually until 2030 based on the company's clinical competitiveness, the official added.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch